AKT1 and cancer: When PD-L1 on cancer cells binds to PD-1 on T cells, it inhibits signaling via the PI3K/AKT and Ras/MEK/ERK pathways downstream of the T cell receptor (TCR) through SHP-1/SHP-2 phosphatases [115,116].